Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells
Authors:
- Johanna RäikkönenJRJohanna Räikkönen
- Markku TaskinenMTMarkku Taskinen
- James E. DunfordJDJames E. Dunford
- Hannu MönkkönenHMHannu Mönkkönen
- Seppo AuriolaSASeppo Auriola
- Jukka MönkkönenJMJukka Mönkkönen
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 407 (4) , 663-667
Abstract
No abstract availableKeywords
Funding Information
- the academy of finland
- the Graduate School in Pharmaceutical Research
- The Finnish Cultural Foundation
This publication has 23 references indexed in Scilit:
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Bisphosphonates in cancer therapyCancer Letters, 2007
- A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen‐containing bisphosphonatesBritish Journal of Pharmacology, 2006
- Treatment of postmenopausal osteoporosisThe Lancet, 2002
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Bisphosphonates and the prevention of metastasisCancer, 2000
- Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate SynthaseArchives of Biochemistry and Biophysics, 2000
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Treatment of patients with Paget's disease of bone.Drugs, 1999
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including RasJournal of Bone and Mineral Research, 1998